Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.

@article{White2003CardiovascularTE,
  title={Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.},
  author={William B White and Gerald A Faich and Jeffrey S. Borer and Robert W. Makuch},
  journal={The American journal of cardiology},
  year={2003},
  volume={92 4},
  pages={411-8}
}
To determine whether the cyclooxygenase-2 (COX-2) inhibitor celecoxib affects cardiovascular thrombotic risk, we analyzed the incidence of cardiovascular events for celecoxib, placebo, and nonsteroidal anti-inflammatory drugs (NSAIDs) in the entire controlled, arthritis clinical trial database for celecoxib. The primary analysis used the Antiplatelet Trialists' Collaboration end points, which include: (1) cardiovascular, hemorrhagic, and unknown deaths, (2) nonfatal myocardial infarction, and… CONTINUE READING
57 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 57 extracted citations

Similar Papers

Loading similar papers…